Schedule of Sales and Operating Income by Operating Segment, Excluding Discontinued Operations |
Revenue and operating income (loss) from continuing operations by operating segment are shown in the table below: | | | | | | | | | | | | | | | | | | Three Months Ended | | Nine Months Ended | | October 4, 2015 | | September 28, 2014 | | October 4, 2015 | | September 28, 2014 | | (In thousands) | Human Health | | | | | | | | Product revenue | $ | 238,553 |
| | $ | 237,312 |
| | $ | 712,207 |
| | $ | 721,449 |
| Service revenue | 105,083 |
| | 99,637 |
| | 298,970 |
| | 288,076 |
| Total revenue | 343,636 |
| | 336,949 |
| | 1,011,177 |
| | 1,009,525 |
| Operating income from continuing operations | 63,147 |
| | 48,089 |
| | 179,560 |
| | 149,979 |
| Environmental Health | | | | | | | | Product revenue | 139,772 |
| | 128,621 |
| | 414,149 |
| | 391,578 |
| Service revenue | 80,028 |
| | 76,479 |
| | 228,917 |
| | 227,726 |
| Total revenue | 219,800 |
| | 205,100 |
| | 643,066 |
| | 619,304 |
| Operating income from continuing operations | 22,838 |
| | 18,540 |
| | 53,606 |
| | 65,725 |
| Corporate | | | | | | | | Operating loss from continuing operations(1) | (10,087 | ) | | (7,853 | ) | | (31,756 | ) | | (35,529 | ) | Continuing Operations | | | | | | | | Product revenue | 378,325 |
| | 365,933 |
| | 1,126,356 |
| | 1,113,027 |
| Service revenue | 185,111 |
| | 176,116 |
| | 527,887 |
| | 515,802 |
| Total revenue | 563,436 |
| | 542,049 |
| | 1,654,243 |
| | 1,628,829 |
| Operating income from continuing operations | 75,898 |
| | 58,776 |
| | 201,410 |
| | 180,175 |
| Interest and other expense, net (see Note 5) | 11,944 |
| | 10,966 |
| | 32,208 |
| | 31,219 |
| Income from continuing operations before income taxes | $ | 63,954 |
| | $ | 47,810 |
| | $ | 169,202 |
| | $ | 148,956 |
|
____________________________ | | (1) | In 2002, Enzo Biochem, Inc. and Enzo Life Sciences, Inc. (collectively, “Enzo”) filed a complaint that alleged that the Company separately and together with other defendants breached distributorship and settlement agreements with Enzo, infringed Enzo's patents, engaged in unfair competition and fraud, and committed torts against Enzo by, among other things, engaging in commercial development and exploitation of Enzo's patented products and technology. The Company entered into a settlement agreement with Enzo dated June 20, 2014 and during fiscal year 2014 paid $7.0 million into a designated escrow account to resolve this matter, of which $3.7 million had been accrued in previous years and $3.3 million was recorded in the second quarter of fiscal year 2014. In addition, the Company incurred $3.4 million of expenses in preparation for the trial during the six months ended June 29, 2014. |
|